Rep. Cummings seeks House hearing on Turing Pharma CEO; Amgen and Allergan say study shows their Avastin biosimilar effective in lung cancer

@FiercePharma: Otsuka prepares to roll out two-drug combo for colorectal cancer. FiercePharmaMarketing story | Follow @FiercePharma

@EricPFierce: ICYMI: Novo to build a $78M insulin pen plant in Iran. FiercePharmaManufacturing story | Follow @EricPFierce

> Amgen ($AMGN) and Allergan ($AGN) said a late-stage study showed their biosimilar candidate of Roche ($RHHBY) blockbuster Avastin was as effective as the original in lung cancer. Story

> ViiV Healthcare says a data from a Phase IIIb/IV study met the endpoint in patients with suppressed HIV when they switched to its once daily Triumeq from an antiretroviral therapy. Release

> Depomed Wednesday reported a decision from patent regulators that it said will help it in its patent-infringement lawsuits against Endo Pharmaceuticals ($ENDP) and Purdue Pharma and their competing painkillers. Report

> U.S. Rep. Elijah E. Cummings is asking the House to hold a hearing with Martin Shkreli, whose company Turing Pharma recently jacked up the price by 5000% of a pill whose users tend to be AIDS sufferers and cancer patients. Release

> England's price watchdog NICE has recommended approval of Daiichi Sankyo's bloodthinner Lixiana to prevent blood clots in adult patients with a certain heart rhythm disorder. Story

Medical Device News

@FierceMedDev: ICYMI: St. Jude nabs CE mark for Infinity DBS for movement disorders, awaits U.S. launch before year end. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI from FierceBiotech: Should Martin Shkreli be allowed to play the Good Samaritan defense? Commentary | Follow @VarunSaxena2

@EmilyWFierce: Human Longevity joins with South African insurer for $250 exome sequencing service. FierceDiagnostics article | Follow @EmilyWFierce

> CliniCloud gets $5M seed round to launch connected medical kit at Best Buy. News

> Institute of Medicine makes suggestions for improving accuracy of medical diagnoses. Item

> Four key medical device recalls of 2015. Report

Biotech News

@FierceBiotech: FierceBiotech Radio with @JohnCFierce on Turing Pharma, Martin Shkreli and the magic of Twitter. More | Follow @FierceBiotech

@JohnCFierce: These Twitter controversies are intense. On CNN, Sky News, CBC and other radio shows to discuss being called a moron. Cheers. | Follow @JohnCFierce

@DamianFierce: The best thing about ABC's exclusive Shkreli story was that NBC ran it 15 minutes earlier. | Follow @DamianFierce

> Amgen and Allergan clear Phase III with an Avastin biosimilar, looking to unseat a blockbuster. More

> Scholar Rock hopes to one-up pharma titans with a muscle-building drug. News

> OncoGenex's drug misses the mark in pancreatic cancer. Story

Biotech Research News

> Uppsala's 'smart' robot tests new cancer drug combos. News

> Epigenomic combo shows promise in mouse model of pancreatic cancer. Story

> An arthritis drug demos potential to help reverse Alzheimer's disease. More

> Experimental drug amps up Afinitor's punch against pancreatic cancer. Article

> Imperial team targets a key culprit involved in Parkinson's. News

Diagnostics News

> Roche's influenza A and B tests get federal permission to be used at the point-of-care. Story

> LabCorp, China's Fosun Pharma, lead Asia-heavy $15B investment in Ativa Medical. More

> Rumor: Private equity owners looking to sell Swiss diagnostics player Unilabs for $1.7B. Article

> Human Longevity joins with South African insurer for $250 exome sequencing service. News

> Sequenom appoints new CEO amid diversification. Story

Pharma Marketing News

> Emmy co-host Mario Lopez spotlights Valeant's Jublia on the red carpet. News

> Fretting about potential Humira pain for AbbVie? Take heart in potential cost cuts. Story

> Apple's ad blocking heats up debate, but what does it mean for pharma? Article

> IMS Health finds mHealth mobile app 'prescriptions' on the rise. Story

> Otsuka prepares to roll out two-drug combo for colorectal cancer. Item

And Finally... Arkansas intends to go ahead and use for lethal injection a Sun Pharma drug despite the company's objection. Story

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

While Novo's Rybelsus launch has slowed due to the pandemic, another version of the med, Ozempic posted strong sales.

AZ sold Atacand and Atacand Plus rights in about 70 countries to Cheplapharm.